Matribhumi Samachar English
The partnership aims to strengthen disease awareness, capacity building and clinical management for overweight and obesity care.
- Empowering healthcare professionals and support staff with evidence-based education and clinical development tools to improve overweight and obesity related health outcomes at scale.
- Establishing a countrywide network of well-structured obesity clinics focused on multidisciplinary care, early diagnosis and long-term patient engagement
Hyderabad, 1st September 2025: Novo Nordisk, the global leader in chronic disease care, today announced a strategic collaboration with Apollo Clinics to launch a comprehensive Obesity Management Program across various cities in India. This initiative aims to address the growing burden of overweight and obesity through a structured, multi-tiered care model focused on empowering individuals living with overweight or obesity and developing specialised programs for obesity care.
With this collaboration, Apollo Clinics and Novo Nordisk will integrate a comprehensive obesity care framework across select centres. As part of this partnership, Apollo Clinics will bring its expertise as a pioneer in running condition management programs and will now provide support like infrastructure, clinical pathways and digital patient support tools to deliver comprehensive evidence-based obesity care. This initiative will also feature dedicated patient awareness campaigns, including educational videos, booklets, and body composition analysis. A QR-enabled platform will provide access to BMI and waist-to-height ratio calculators, connecting users to appropriate care pathways.
Dr Maya Sharma, Vice President – Clinical, Medical & Regulatory, Novo Nordisk India; said, “The prevalence of obesity continues to rise in India, yet clinical recognition remains inadequate. Novo Nordisk aims to transform how obesity is understood, diagnosed and managed at the primary level across the nation. The mission of this partnership with Apollo Clinics is to equip healthcare professionals with robust clinical education, patient-centric tools and infrastructure support they need to deliver personalised and evidence-based healthcare interventions that go beyond symptom management. Together, we hope to drive lasting behavioural and health outcomes, ultimately improving quality of life for millions of Indians living with overweight or obesity.”
Mr Sriram Iyer, CEO – Apollo Health & Lifestyle Limited; said, “This partnership reinforces our long-standing commitment to address the complex challenge of Obesity and weight related conditions in India and will help to address chronic lifestyle diseases with innovation and clinical excellence. Apollo Clinics with its wide-reaching network along with Novo Nordisk’s global expertise in obesity care, plans to deliver more structured, evidence-based support to patients living with obesity across India. Together, we look forward to creating a care model that is accessible, sustainable and truly patient-centric.”
Obesity in India affects more than 250 million adults[1], and is linked to over 230 health complications[2], including cardiovascular disease, diabetes, cancer and obstructive sleep apnoea. The proportion of individuals with overweight and obesity in India shows significant variation by state, ranging from 8% to 50%, and spans all demographics, including men and
women across both rural and urban populations.[3] The economic burden of obesity-related diseases in India is projected to reach ₹36,000 crores by 2030[4].
With a shared commitment to driving change in obesity care, Novo Nordisk and Apollo Clinics are advancing the new programme, which integrates innovative treatments, patient education and systematic advocacy. By recognising obesity as a serious, chronic disease rather than a lifestyle issue, the partnership aims to empower both healthcare providers and patients with the tools needed for long-term and sustainable health outcomes.
About Novo Nordisk
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 76,300 people in 80 countries and markets its products in around 170 countries. Novo Nordisk’s B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO)
For more information, visit novonordisk.co.in, Facebook, X, LinkedIn and YouTube.
About Apollo Clinics
Apollo Clinics founded in 2002, is a multispecialty clinic with India largest network of primary care clinics. It is committed to providing consistently superior quality health care services along with addressing the day-to-day health care needs of the family. To maximize convenience and comfort, Apollo Clinic offers integrated model and facilities for specialist consultation, diagnostics, preventive health checks and pharmacy, all under one roof.
The brand encourages the community towards preventive health care with the launch of predictive, scientific and precision based health checks. Apollo Clinics run a large network of centers with over 300+ clinics, both owned and franchised in India and overseas. In a span of thirteen years the brand has over 3 million+ health check under its kitty.
[1] Anjana RM et al. Metabolic non-communicable disease health report of India: the ICMR-INDIAB national cross-sectional study (ICMR-INDIAB-17). The Lancet Diabetes & Endocrinology. 2023 Jul 1;11(7):474-89.
[2] Horn et al. Postgrad Med 2022;134:359–75
[3] National Family Health Survey (NFHS-5) India Report, Round 5, 2019-21
[4] World Obesity Federation. Economic impact of overweight and obesity: global, regional, and country analysis. 2023
Featured Article
